Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Gesundheitswesen ; 86(6): 430-435, 2024 Jun.
Article in German | MEDLINE | ID: mdl-38467146

ABSTRACT

In addition to unemployment, poor living and housing conditions and increased morbidity, precarious living situations are often characterized by a lack of or inadequate health insurance. In the Federal Republic of Germany, there is a difficult-to-quantify number of people who, for various reasons, have only limited health insurance coverage or none at all. Those affected include German citizens, EU citizens, and non-EU-citizens who are frequently homeless and/or undocumented. Health care for those groups is predominantly provided outside the German health care system by voluntary non-governmental and welfare organizations. Several German states and municipalities together with non-governmental organizations have addressed this problem by establishing clearing centers often combined with cost reimbursement for medical treatment. In this article, five of these projects are analysed and compared with each other with regard to their structure and mode of operation. The results show that many people can be helped in this way, but in order to meet the high and increasing demand, effort must be put towards more comprehensive solutions as well as on the expansion and sustainability of these projects. At the same time, there is an urgent need to improve statistical and epidemiological data.


Subject(s)
Health Services Accessibility , Germany , Health Services Accessibility/statistics & numerical data , Humans , Delivery of Health Care/organization & administration , National Health Programs
2.
Dtsch Arztebl Int ; 117(29-30): 509, 2020 07 20.
Article in English | MEDLINE | ID: mdl-33087233
3.
Gynecol Endocrinol ; 33(7): 503-509, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28347197

ABSTRACT

Between the age of 40 and 55 years, women experience important changes in their lives. This period, which corresponds to the perimenopause for most women, is associated with the risk of iron deficiency anemia (IDA). The clinical presentation of anemia can be misleading, and the underlying cause, particularly bleeding, is frequently treated without concomitant iron prescription. Iron deficiency (ID) remains a social and economic burden in European countries. Underdiagnosed and undertreated, this problem has a strong negative impact on women's quality of life. The risk factors for ID are well known. The physician's role is essential in recognizing the symptoms, identifying the risk factors, detecting IDA by testing hemoglobin, and evaluating the degree of ID by measuring serum ferritin (SF). Iron therapy treats the anemia and restores iron stores, thus decreasing symptoms such as fatigue and restoring quality of life. Among the available forms of iron, evidence is in favor of ferrous sulfate in a slow release formulation, which is well-tolerated and results in good adherence, a key factor for efficacious supplementation.


Subject(s)
Anemia, Iron-Deficiency/diagnosis , Ferritins/blood , Iron/therapeutic use , Perimenopause/blood , Quality of Life , Adult , Anemia, Iron-Deficiency/blood , Anemia, Iron-Deficiency/drug therapy , Female , Humans , Middle Aged
4.
J Perinat Med ; 44(3): 309-14, 2016 Apr.
Article in English | MEDLINE | ID: mdl-25803071

ABSTRACT

The conditions of iron deficiency are highly incident in pregnancy with elevated risks for preterm birth and low birth weight. In our recent study, we found 6% of participants having anemia, whereas between 39% and 47% showed iron deficiency without anemia. In many countries in prenatal care solely hemoglobin (Hb) measurement is applied. For the gynecologists till date there is no indication to determine other markers (e.g., serum-ferritin). As iron deficiency results from an imbalance between intake and loss of iron, our aim was to find out if the risk of iron deficiency conditions can be estimated by a diet history protocol as well as questionnaires to find about iron loss. We found that the risk of having iron deficiency in upper gestational week (>=21) increased by a factor of five. Thus, additional diagnostics should be done in this group by now. Using the questionnaire as a screening instrument, we further estimated the probability of disease in terms of a positive likelihood ratio (LR+). The positive LR for the group below 21th week of gestation is 1.9 thus, increasing the post-test probability to 52% from 36% as before. Further research based on higher sample sizes will show if the ratios can be increased further.


Subject(s)
Iron Deficiencies , Pregnancy Complications/blood , Pregnancy Complications/etiology , Anemia, Iron-Deficiency/blood , Anemia, Iron-Deficiency/complications , Anemia, Iron-Deficiency/diagnosis , Biomarkers/blood , Diet , Feasibility Studies , Female , Humans , Iron, Dietary/administration & dosage , Likelihood Functions , Pregnancy , Pregnancy Complications/diagnosis , Risk Factors , Surveys and Questionnaires
6.
PLoS One ; 8(2): e55633, 2013.
Article in English | MEDLINE | ID: mdl-23405185

ABSTRACT

INTRODUCTION: Tanzanian guidelines for prevention of mother-to-child-transmission of HIV (PMTCT) recommend an antiretroviral combination regimen involving zidovudine (AZT) during pregnancy, single-dosed nevirapine at labor onset, AZT plus Lamivudine (3TC) during delivery, and AZT/3TC for 1-4 weeks postpartum. As drug toxicities are a relevant concern, we assessed hematological alterations in AZT-exposed women and their infants. METHODS AND MATERIALS: A cohort of HIV-positive women, either with AZT intake (n = 82, group 1) or without AZT intake (n = 62, group 2) for PMTCT during pregnancy, was established at Kyela District Hospital, Tanzania. The cohort also included the infants of group 1 with an in-utero AZT exposure ≥4 weeks, receiving AZT for 1 week postpartum (n = 41), and infants of group 2 without in-utero AZT exposure, receiving a prolonged 4-week AZT tail (n = 58). Complete blood counts were evaluated during pregnancy, birth, weeks 4-6 and 12. RESULTS: For women of group 1 with antenatal AZT intake, we found a statistically significant decrease in hemoglobin level, red blood cells, white blood cells, granulocytes, as well as an increase in red cell distribution width and platelet count. At delivery, the median red blood cell count was significantly lower and the median platelet count was significantly higher in women of group 1 compared to group 2. At birth, infants from group 1 showed a lower median hemoglobin level and granulocyte count and a higher frequency of anemia and granulocytopenia. At 4-6 weeks postpartum, the mean neutrophil granulocyte count was significantly lower and neutropenia was significantly more frequent in infants of group 2. CONCLUSIONS: AZT exposure during pregnancy as well as after birth resulted in significant hematological alterations for women and their newborns, although these changes were mostly mild and transient in nature. Research involving larger cohorts is needed to further analyze the impact of AZT-containing regimens on maternal and infant health.


Subject(s)
Anti-HIV Agents/administration & dosage , HIV Infections/prevention & control , HIV-1/drug effects , Infectious Disease Transmission, Vertical/prevention & control , Mothers , Pregnancy Complications, Infectious/prevention & control , Prenatal Exposure Delayed Effects/prevention & control , Adolescent , Adult , Anti-HIV Agents/pharmacology , Blood Cell Count , Drug Therapy, Combination , Female , HIV Infections/drug therapy , HIV Infections/transmission , HIV-1/genetics , Hematocrit , Hematologic Diseases/chemically induced , Hematologic Diseases/prevention & control , Hematologic Tests , Hemoglobins/analysis , Humans , Infant , Infant, Newborn , Pregnancy , Pregnancy Complications, Infectious/drug therapy , Pregnancy Outcome , Tanzania , Young Adult , Zidovudine/administration & dosage , Zidovudine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...